Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Liabilities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $84.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 223.19% to $84.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $84.4 million, a 223.19% increase, with the full-year FY2025 number at $84.4 million, up 223.19% from a year prior.
  • Other Non-Current Liabilities was $84.4 million for Q4 2025 at ImmunityBio, down from $115.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $115.2 million in Q3 2025 to a low of $288000.0 in Q1 2022.
  • A 5-year average of $27.1 million and a median of $1.1 million in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 13725.58% in 2024, then plummeted 98.91% in 2025.
  • ImmunityBio's Other Non-Current Liabilities stood at $411000.0 in 2021, then surged by 38.44% to $569000.0 in 2022, then skyrocketed by 94.9% to $1.1 million in 2023, then surged by 2255.28% to $26.1 million in 2024, then skyrocketed by 223.19% to $84.4 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Non-Current Liabilities are $84.4 million (Q4 2025), $115.2 million (Q3 2025), and $710000.0 (Q2 2025).